Close menu




June 25th, 2024 | 07:00 CEST

300%-Opportunity, problems, and the German Chancellor: Bayer, BioNTech, and Cardiol Therapeutics

  • Biotechnology
  • Pharma
Photo credits: BioNTech SE

Bayer is making positive headlines for a change. Following takeovers in cell and gene therapy, the Company is investing in Berlin and has brought the renowned Charité Hospital on board. Federal Chancellor Olaf Scholz gives the go-ahead for the project. Can the share benefit from this? The sell-off in Cardiol Therapeutics shares after positive study results was a surprise. Analysts are enthusiastic, raising price targets and seeing 300% potential. On the other hand, BioNTech shares are currently not an obvious buy. And now there are also problems with the FDA in the US. This is causing alarm among shareholders and impacting the share.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Cardiol Therapeutics: More than 300% share price potential after study data

    Following convincing study data, the analysts at First Berlin have substantially increased their price target for Cardiol Therapeutics shares. The experts have raised the fair value from USD 3.60 to USD 8.50. At the current price level of USD 2.00, the analysts believe the share price could jump by more than 300%. Accordingly, their recommendation is "Buy". However, the sell-off of the shares after the study data was surprising – sometimes, things turn out differently than you think on the stock market. However, from the analysts' point of view, this represents a buying opportunity.

    For First Berlin, the data announced from the Phase II MAvERIC-Pilot open-label US study of Cardiol's lead drug candidate, CardiolRx™, for the treatment of recurrent pericarditis (inflammation of the pericardium) were excellent. The efficacy of CardiolRx™ on two key endpoints would be similar in magnitude of improvement to the biologic rilonacept. Rilonacept has already received approval from the US Food and Drug Administration (FDA) and is in commercial use. However, CardiolRx™ would have a significantly better tolerability and side effect profile. The analysts, therefore, see the potential for CardiolRx™ to replace rilonacept as a second-line therapy for recurrent pericarditis following approval. Rilonacept generated sales of around USD 233 million in 2023, the third year after FDA approval. Based on the benefits, the analysts believe that CardiolRx™ has even higher revenue potential; especially if CardiolRx™ were also approved in Europe.

    Commenting on the trial data, Cardiol CEO David Elsley said: "We are particularly pleased to announce the primary endpoint data from the MAvERIC-Pilot study. These data showed that oral administration of our small molecule CardiolRx™ led to a significant reduction in pain and inflammation associated with pericarditis. Due to the clinically significant effect of CardiolRx™ on the key symptom of this highly debilitating disease, we now anticipate that the totality of the data from the MAvERIC-Pilot study will support progression to a Phase III study of CardiolRx™, which we hope will achieve our goal of providing thousands of pericarditis patients with a more accessible and non-immunosuppressive treatment option." By the way, the price target of USD 8.50 (Link to study) for Cardiol shares is not the highest. H.C. Wainwright even believes the share could reach USD 9.00.

    Bayer: German Chancellor speaks out

    Despite the price setback, Cardiol shares have more than doubled in the current year, and, as described above, analysts believe that the stock is capable of much more. There is still no sign of this in Bayer shares. Nevertheless, Germany's former most valuable company has recently made positive headlines again. For example, the go-ahead was given in Berlin for a translational center for gene and cell therapies. It is being set up jointly with the Charité Hospital and funded by the federal government and the state of Berlin. The joint project aims to make the treatment options of these pioneering technologies available to patients more quickly and, at the same time, to establish a leading biotech ecosystem for innovative therapies in Berlin.

    Federal Chancellor Olaf Scholz: "With the launch of the new Translational Center, we are also celebrating a unique form of cooperation between science, industry and politics. This institution will become the core of an entire organism of gene and cell-based therapies. For this, we need scientists and entrepreneurs who see both the smallest details in the cell nucleus and the big picture: the medicine of the future, which provides answers to the big questions already posed by Rudolf Virchow. It is good that we have both here in Germany: courageous research and innovative companies. I wish you every success with this visionary project!" In recent years, Bayer has strengthened its position in cell and gene therapy through the acquisitions of BlueRock Therapeutics and Asklepios Biopharmaceutical, among others.

    BioNTech: Problems with the FDA

    BioNTech shares currently lack sustained positive momentum. On the contrary, a cancer drug candidate recently caused alarm in the US. BioNTech announced that a clinical Phase I study for the candidate BNT326/YL202 has been partially suspended by the FDA due to safety concerns. The reason is that there are concerns about the safety of the drug at higher doses. The study is investigating an agent for the treatment of advanced or metastatic EGFR-mutated non-small cell lung cancer or HR+/HER2 breast cancer. BioNTech and Suzhou MediLink signed an agreement for the development of BNT326 only last October. The study is on hold while MediLink resolves the FDA's concerns.

    *Before that, however, there was also positive research news: Genmab and BioNTech announced the first data from an ongoing Phase II trial with the bispecific antibody test preparation Acasunlimab. The trial is investigating the candidate GEN1046/BNT311 as monotherapy and in combination with pembrolizumab in patients with PD-L(1)-positive metastatic non-small cell lung cancer who have progressed after one or more prior anti-PD(L)1 lines of therapy. At the end of the observation period (data cut-off), the data showed a 12-month overall survival rate of 69%, a median overall survival rate of 17.5 months and an overall response rate of 30%. BioNTech co-founder and CMO Prof. Dr. Özlem Türeci: "Most patients with metastatic non-small cell lung cancer have limited treatment options after discontinuing first-line therapy with checkpoint inhibitors. For these patients, chemotherapy remains the main treatment option despite limited efficacy and significant toxicity. The data from our Phase II study show that combining acasunlimab with PD-L1 inhibition may be a suitable approach for this heavily pre-treated patient population*."


    At Bayer and BioNTech, there is currently no urgency to buy. The situation with Cardiol Therapeutics is much more exciting. The study results, and analysts' price targets do not match the short-term sell-off. This could represent an exciting buying opportunity.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 17th, 2024 | 07:30 CEST

    Siemens Energy share down 50%? Now time to buy Rheinmetall, Bayer, and Saturn Oil + Gas?

    • Mining
    • Oil
    • Defense
    • Pharma
    • renewableenergies

    Can the Siemens Energy share halve in value? At least, that is what the analysts at Bernstein think, who have set a price target of EUR 15. After a strong rally, the focus is now back on the Company's problem areas, such as India. Rheinmetall, on the other hand, is recommended as a "Buy". Can the armaments group thus end its sideways movement? In an initial study, analysts see around 50% upside potential for Saturn Oil & Gas. The oil company intends to significantly increase its free cash flow in the coming years but is considered undervalued compared to its peers. Some analysts see even more potential. Analysts are cautious about Bayer shares. In addition to the well-known legal disputes, operational issues are also a burden.

    Read

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.

    Read

    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.

    Read